Ankylosing spondylitis, spondyloarthropathy, spondyloarthritis, or spondylarthritis: What's in a name? Joint Bone Spine ,
Prevalence of spondyloarthropathies in France: 2001, Prevalence of spondyloarthropathies in France, pp.1431-1436, 2001. ,
DOI : 10.1136/ard.2004.029207
Evaluation of Diagnostic Criteria for Ankylosing Spondylitis, Arthritis & Rheumatism, vol.2, issue.4, pp.361-369, 1984. ,
DOI : 10.1002/art.1780270401
The European Spondylarthropathy Study Group Preliminary Criteria for the Classification of Spondylarthropathy, Arthritis & Rheumatism, vol.57, issue.10, pp.1218-1245, 1991. ,
DOI : 10.1002/art.1780341003
Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup, J Rheumatol, vol.15, pp.1109-1123, 1988. ,
Criteria of the classification of spondylarthropathies, Rev Rhum Mal Osteoartic, vol.57, pp.85-94, 1990. ,
Clinical History as a Screening Test for Ankylosing Spondylitis, JAMA: The Journal of the American Medical Association, vol.237, issue.24, pp.2613-2617, 1977. ,
DOI : 10.1001/jama.1977.03270510035017
Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years, Arthritis & Rheumatism, vol.10, issue.11, pp.3413-3421, 2008. ,
DOI : 10.1002/art.24024
The early disease stage in axial spondylarthritis: Results from the german spondyloarthritis inception cohort, Arthritis & Rheumatism, vol.33, issue.3, pp.717-744, 2009. ,
DOI : 10.1002/art.24483
Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve???week randomized, double???blind, placebo???controlled trial followed by an open???label extension up to week fifty???two, Arthritis & Rheumatism, vol.58, issue.7, pp.1981-91, 2008. ,
DOI : 10.1002/art.23606
How to diagnose axial spondyloarthritis early, Annals of the Rheumatic Diseases, vol.63, issue.5, pp.535-578, 2004. ,
DOI : 10.1136/ard.2003.011247
The challenge of diagnosis and classification in early ankylosing spondylitis: Do we need new criteria?, Arthritis & Rheumatism, vol.67, issue.4, pp.1000-1008, 2005. ,
DOI : 10.1002/art.20990
Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group, Annals of the Rheumatic Diseases, vol.68, issue.10, pp.1520-1527, 2009. ,
DOI : 10.1136/ard.2009.110767
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection, Annals of the Rheumatic Diseases, vol.68, issue.6, pp.777-83, 2009. ,
DOI : 10.1136/ard.2009.108233
Performance of the Assessment in Spondyloarthritis International Society Classification for Axial and Peripheral Spondyloarthritis in an Established Clinical Cohort: Comparison with Criteria Sets of Amor and the European Spondylarthropathy Study Group, The Journal of Rheumatology, vol.39, issue.4, pp.816-837 ,
DOI : 10.3899/jrheum.111088
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis, Annals of the Rheumatic Diseases, vol.70, issue.6, pp.896-904, 2011. ,
DOI : 10.1136/ard.2011.151027
A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index, J Rheumatol, vol.21, pp.2286-91, 1994. ,
Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives, Rheumatology, vol.44, issue.6, pp.789-95, 2005. ,
DOI : 10.1093/rheumatology/keh595
The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index, Arthritis Care & Research, vol.24, issue.2, pp.154-159, 2004. ,
DOI : 10.1002/art.20233
Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations, Annals of the Rheumatic Diseases, vol.68, issue.11, pp.1701-1707, 2009. ,
DOI : 10.1136/ard.2008.099226
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis, Annals of the Rheumatic Diseases, vol.68, issue.1, pp.18-24, 2009. ,
DOI : 10.1136/ard.2008.094870
Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores, Annals of the Rheumatic Diseases, vol.70, issue.1, pp.47-53, 2011. ,
DOI : 10.1136/ard.2010.138594
Comment definir l'activité d'une spondylarthrite ? Revue du Rhumatisme, pp.215-239 ,
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis, Annals of the Rheumatic Diseases, vol.68, issue.12, pp.1811-1819, 2009. ,
DOI : 10.1136/ard.2008.100826
How to measure disease activity in axial spondyloarthritis?, Current Opinion in Rheumatology, vol.23, issue.4, pp.339-384, 2011. ,
DOI : 10.1097/BOR.0b013e3283470f23
2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis, Annals of the Rheumatic Diseases, vol.70, issue.6, pp.905-913, 2011. ,
DOI : 10.1136/ard.2011.151563
Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria, Rheumatology, vol.51, issue.8, pp.1479-83, 2012. ,
DOI : 10.1093/rheumatology/kes057
Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis, Arthritis & Rheumatism, vol.26, issue.8, pp.1876-86, 2001. ,
DOI : 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F
Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel, Annals of the Rheumatic Diseases, vol.62, issue.3, pp.215-236, 2003. ,
DOI : 10.1136/ard.62.3.215
Development and preselection of criteria for short term improvement after anti-TNF?? treatment in ankylosing spondylitis, Annals of the Rheumatic Diseases, vol.63, issue.11, pp.1438-1482, 2004. ,
DOI : 10.1136/ard.2003.016717
Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis, J Rheumatol, vol.26, pp.980-984, 1999. ,
Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis, J Rheumatol, vol.26, pp.971-975, 1999. ,
Validity aspects of erythrocyte sedimentation rate and C reactive protein in ankylosing spondylitis: a literature review, J Rheumatol, vol.26, pp.966-70, 1999. ,
The DESIR cohort: A 10-year follow-up of early inflammatory back pain in France: Study design and baseline characteristics of the 708 recruited patients, Joint Bone Spine, vol.78, issue.6, pp.598-603, 2011. ,
DOI : 10.1016/j.jbspin.2011.01.013
URL : https://hal.archives-ouvertes.fr/hal-00730858
An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis, Annals of the Rheumatic Diseases, vol.65, issue.12, pp.1620-1625, 2006. ,
DOI : 10.1136/ard.2005.042630
Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein, Rheumatology, vol.49, issue.3, pp.536-577, 2010. ,
DOI : 10.1093/rheumatology/kep393
A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases, Clin Exp Rheumatol, vol.23, pp.188-94, 2005. ,
Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid A protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis, Arthritis Care & Research, vol.2, issue.11, pp.1484-90, 2009. ,
DOI : 10.1002/art.24838
Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis, Annals of the Rheumatic Diseases, vol.69, issue.7, pp.1338-1379, 2010. ,
DOI : 10.1136/ard.2009.120139
Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry, Annals of the Rheumatic Diseases, vol.69, issue.11, pp.2002-2010, 2010. ,
DOI : 10.1136/ard.2009.124446
Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study, Arthritis Research & Therapy, vol.13, issue.3, p.94, 2011. ,
DOI : 10.1136/ard.2008.089979
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor ?? blockers in ankylosing spondylitis, Annals of the Rheumatic Diseases, vol.63, issue.6, pp.665-70, 2004. ,
DOI : 10.1136/ard.2003.016386
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatism, vol.62, issue.7, p.213646, 2006. ,
DOI : 10.1002/art.21913
Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT), Arthritis & Rheumatism, vol.50, issue.2, pp.582-91, 2005. ,
DOI : 10.1002/art.20852
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial, Arthritis & Rheumatism, vol.44, issue.11, pp.3230-3236, 2003. ,
DOI : 10.1002/art.11325
Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report, Rheumatology, vol.46, issue.8, pp.1309-1324, 2007. ,
DOI : 10.1093/rheumatology/kem084
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1), Annals of the Rheumatic Diseases, vol.72, issue.6, p.22772328, 2012. ,
DOI : 10.1136/annrheumdis-2012-201766
Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor ?? inhibitors, Annals of the Rheumatic Diseases, vol.69, issue.6, pp.1065-71, 2010. ,
DOI : 10.1136/ard.2009.111187
The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-?? inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China, Rheumatology, vol.50, issue.8, pp.1466-72, 2011. ,
DOI : 10.1093/rheumatology/ker087
Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial, Rheumatology, vol.51, issue.10, pp.1894-90522772319, 2012. ,
DOI : 10.1093/rheumatology/kes142
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis, Annals of the Rheumatic Diseases, vol.70, issue.6, pp.896-904, 2011. ,
DOI : 10.1136/ard.2011.151027
Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis, International Journal of Rheumatic Diseases, vol.44, issue.3, pp.240-245, 2010. ,
DOI : 10.1111/j.1756-185X.2010.01537.x